세계의 레날리도마이드(Lenalidomide) 시장 : 시장 규모 분석(종류별, 용도별, 지역별) 및 예측(2022-2032년)

Global Lenalidomide Market is valued approximately at USD 12.39 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.60% over the forecast period 2024-2032. Lenalidomide, a derivative of thalidomide, has transformed the therapeutic landscape for patients suffering from hematologic malignancies, most notably multiple myeloma and myelodysplastic syndromes. This immunomodulatory agent, known for its anti-inflammatory, anti-angiogenic, and tumoricidal properties, has increasingly become the cornerstone of combination regimens across both frontline and relapsed settings. The drug's adaptability in being administered as oral monotherapy or in synergy with corticosteroids and proteasome inhibitors has allowed oncologists to optimize treatment outcomes while managing patient tolerance and quality of life. As the global incidence of blood cancers rises, Lenalidomide's clinical relevance continues to deepen.

Market dynamics are being shaped by a potent mix of factors ranging from the broadening scope of therapeutic indications to the increasing availability of biosimilar and generic alternatives. Pharmaceutical companies are rigorously engaged in lifecycle management strategies including the introduction of new dosages (such as 5mg, 10mg, 15mg, and 25mg capsules) and extended combination therapies to extend patent longevity and commercial exclusivity. Furthermore, ongoing clinical trials investigating Lenalidomide's potential applications in solid tumors and autoimmune conditions suggest an expanding future market horizon. However, pricing pressures, regulatory scrutiny on high-cost oncology treatments, and emerging competition from novel agents such as CAR-T therapies may present roadblocks to sustained growth.

Lenalidomide's well-documented efficacy in refractory and relapsed cancer cases continues to bolster its adoption among oncologists. What sets it apart is not only its robust clinical data but also its oral administration-offering ease of use and patient convenience in outpatient settings. In low- and middle-income countries, where access to complex biologics may be limited, the rise of generic lenalidomide is helping bridge treatment disparities. Meanwhile, health systems in high-income countries are transitioning toward value-based care models that emphasize outcomes and cost-effectiveness, prompting renewed evaluations of Lenalidomide's long-term economic value.

Geographically, North America remains at the forefront of the Lenalidomide market owing to early drug approvals, advanced diagnostic infrastructure, and a strong presence of major market players. The United States, in particular, continues to be a key revenue contributor driven by a high burden of multiple myeloma and broad insurance coverage for cancer therapies. Europe follows closely, underpinned by favorable reimbursement policies and growing geriatric cancer demographics. Asia Pacific is poised to emerge as the fastest-growing regional market, driven by increasing cancer prevalence, rising healthcare investments, and expanded access to generics in markets like India, China, and Japan.

Major market player included in this report are:

• Celgene Corporation (a Bristol-Myers Squibb Company)
• Natco Pharma Ltd.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Intas Pharmaceuticals Ltd.
• Mylan N.V.
• Glenmark Pharmaceuticals Ltd.
• Apotex Inc.
• Zydus Lifesciences Ltd.
• Lupin Pharmaceuticals, Inc.
• Novartis AG
• Hikma Pharmaceuticals PLC

The detailed segments and sub-segment of the market are explained below:

By Type

• 5mg Capsules
• 10mg Capsules
• 15mg Capsules
• 25mg Capsules

By Application

• Multiple Myeloma
• Myelodysplastic Syndromes
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Lenalidomide Market Executive Summary

• 1.1. Global Lenalidomide Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type (5mg, 10mg, 15mg, 25mg Capsules)
  • 1.3.2. By Application
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Lenalidomide Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Lenalidomide Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising incidence of hematologic malignancies
  • 3.1.2. Expansion of combination therapy regimens
  • 3.1.3. Growth of generic and biosimilar introductions
• 3.2. Market Challenges
  • 3.2.1. High treatment costs and reimbursement pressures
  • 3.2.2. Regulatory scrutiny on safety and off-label use
  • 3.2.3. Competition from novel immunotherapies (CAR-T, bispecifics)
• 3.3. Market Opportunities
  • 3.3.1. Emerging indications in solid tumors and autoimmune diseases
  • 3.3.2. Expansion in Asia Pacific due to improving access
  • 3.3.3. Lifecycle management via new dosage strengths and formulations

Chapter 4. Global Lenalidomide Market Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's Model
  • 4.1.7. Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspectives
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Lenalidomide Market Size & Forecasts by Type (2022-2032)

• 5.1. Segment Dashboard
• 5.2. 5mg Capsules Revenue Trend Analysis, 2022 & 2032
• 5.3. 10mg Capsules Revenue Trend Analysis, 2022 & 2032
• 5.4. 15mg Capsules Revenue Trend Analysis, 2022 & 2032
• 5.5. 25mg Capsules Revenue Trend Analysis, 2022 & 2032

Chapter 6. Global Lenalidomide Market Size & Forecasts by Application (2022-2032)

• 6.1. Segment Dashboard
• 6.2. Multiple Myeloma Revenue Trend Analysis, 2022 & 2032
• 6.3. Myelodysplastic Syndromes Revenue Trend Analysis, 2022 & 2032
• 6.4. Others Revenue Trend Analysis, 2022 & 2032

Chapter 7. Global Lenalidomide Market Size & Forecasts by Region (2022-2032)

• 7.1. North America Lenalidomide Market
  • 7.1.1. U.S. Market (2022-2032)
  • 7.1.2. Canada Market (2022-2032)
• 7.2. Europe Lenalidomide Market
  • 7.2.1. U.K. Market
  • 7.2.2. Germany Market
  • 7.2.3. France Market
  • 7.2.4. Spain Market
  • 7.2.5. Italy Market
  • 7.2.6. Rest of Europe Market
• 7.3. Asia Pacific Lenalidomide Market
  • 7.3.1. China Market
  • 7.3.2. India Market
  • 7.3.3. Japan Market
  • 7.3.4. Australia Market
  • 7.3.5. South Korea Market
  • 7.3.6. Rest of Asia Pacific Market
• 7.4. Latin America Lenalidomide Market
  • 7.4.1. Brazil Market
  • 7.4.2. Mexico Market
  • 7.4.3. Rest of Latin America Market
• 7.5. Middle East & Africa Lenalidomide Market
  • 7.5.1. Saudi Arabia Market
  • 7.5.2. South Africa Market
  • 7.5.3. Rest of Middle East & Africa Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Celgene Corporation (BMS)
  • 8.1.2. Natco Pharma Ltd.
  • 8.1.3. Cipla Ltd.
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Celgene Corporation (Bristol-Myers Squibb)
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Natco Pharma Ltd.
  • 8.3.3. Cipla Ltd.
  • 8.3.4. Dr. Reddy's Laboratories Ltd.
  • 8.3.5. Sun Pharmaceutical Industries Ltd.
  • 8.3.6. Teva Pharmaceutical Industries Ltd.
  • 8.3.7. Aurobindo Pharma Ltd.
  • 8.3.8. Intas Pharmaceuticals Ltd.
  • 8.3.9. Mylan N.V.
  • 8.3.10. Glenmark Pharmaceuticals Ltd.
  • 8.3.11. Apotex Inc.
  • 8.3.12. Zydus Lifesciences Ltd.
  • 8.3.13. Lupin Pharmaceuticals, Inc.
  • 8.3.14. Novartis AG
  • 8.3.15. Hikma Pharmaceuticals PLC

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes